ZURICH (dpa-AFX) - The major Swiss bank UBS has left its rating for Morphosys shares at "Buy" with a target price of 47 euros. Analyst Xian Deng wrote this in her Monday morning commentary on the highly anticipated presentation of the pelabresib trial data at the annual meeting of the US Hematology Society. There is still probably no real explanation for the problems with the secondary target in the high-risk group of myelofibrosis patients, she said. However, she considers the overall data from the study to be positive, particularly in terms of the improvement in anemia. This is a key point for the safety profile and also for the quality of life of the patients./ag/gl

Publication of the original study: 11.12.2023 / 02:36 / GMT First dissemination of the original study: 11.12.2023 / 02:36 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------